Novo Nordisk A/S
เพิ่มขึ้น

NVO - buying quality compounder during panic

Financials great, P/E 20 is very reasonable. Top line 20%+, LLY competition threats seems exaggerated. Last time was this oversold in 2017 and quickly rebounded. Impossible to replicate knowledge and ability to innovate. Started entry position at 78.5, will be DCA until it finds the bottom (if not already)

Happy weekend
Fundamental AnalysisTechnical Indicators

คำจำกัดสิทธิ์ความรับผิดชอบ